{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-049436","form_type":"8-K","ticker":"ADGM","cik":"0002006986","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.672626+00:00","generated_at":"2026-05-21T06:06:28.886388+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adagio Medical Q1 net loss $7.7M; FDA breakthrough device designation","bullets":["Net loss of $7.7M ($0.50 per share) vs $8.0M ($10.28 per share) in Q1 2024.","Cash and cash equivalents $13.0M as of March 31, 2025.","FDA granted Breakthrough Device Designation for vCLAS Cryoablation System for ventricular tachycardia.","FULCRUM-VT pivotal study surpassed 50% enrollment; completion on track for H2 2025.","Hired Deborah Kaster as Chief Business Officer; corporate prioritization on FULCRUM-VT trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-049436","json":"https://secwatch.observer/filing/0001104659-25-049436.json","markdown":"https://secwatch.observer/filing/0001104659-25-049436.md","text":"https://secwatch.observer/filing/0001104659-25-049436.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000110465925049436/0001104659-25-049436-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000110465925049436/tm2515197d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T06:06:28.886388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}